Hepatitis C virus (HCV) infection in bone marrow transplant patients after transfusions from anti-HCV-positive blood donors.
In March 1992, 12 bone marrow transplant patients at the Fred Hutchinson Cancer Research Center received blood components from donors who were anti-HCV-nonreactive by first generation ELISA but whose serum later tested anti-HCV-reactive to a second generation ELISA. All these blood components were further tested for anti-HCV using a second-generation RIBA and for HCV RNA by polymerase chain reaction. Recipient sera were tested for HCV RNA prior to and following blood component infusion. Blood components from four donors were positive for HCV RNA. All recipients of HCV RNA-positive blood components became viremic on the first day tested post-infusion. In addition, two recipients of HCV RNA-negative blood components tested HCV RNA-positive both pre- and post-infusion. Viremia persisted up to the time of death or day 100 in five of the six patients who were HCV RNA-positive post-transplant. No HCV RNA-positive recipient developed symptomatic acute hepatitis, and only two had aminotransferase elevations consistent with chronic hepatitis. We conclude that HCV RNA-positivity in blood components accurately predicts transmission of virus. Infection with HCV did not adversely affect short-term patient outcome following bone marrow transplantation.